| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SATTERFIELD THOMAS A JR | 9.4% | +58% | $5,296,658 | +$3,141,967 | 3,115,681 | +146% | Thomas A. Satterfield, Jr. | 30 Jun 2025 |
| Auerbach Shalom | 8.5% | -14% | $4,899,953 | -$18,300 | 2,677,570 | -0.37% | Shalom Auerbach | 29 Jul 2025 |
| Ayala Pharmaceuticals, Inc. | 10% | $4,328,430 | 2,164,215 | AYALA PHARMACEUTICALS, INC. | 09 Apr 2025 |
As of 30 Sep 2025, 25 institutional investors reported holding 1,563,221 shares of OS Therapies Inc - Common Stock, par value $0.001 per share (OSTX). This represents 5% of the company’s total 31,500,824 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 13,917 | $19,484 | -$4,176 | $1.40 | 2 |
| 2025 Q3 | 1,563,221 | $3,065,164 | +$1,884,295 | $1.96 | 25 |
| 2025 Q2 | 603,727 | $1,134,576 | +$402,668 | $1.88 | 13 |
| 2025 Q1 | 389,286 | $599,294 | +$293,725 | $1.54 | 6 |
| 2024 Q4 | 145,004 | $620,617 | +$9,243 | $4.28 | 5 |
| 2024 Q3 | 160,043 | $447,782 | +$447,782 | $2.80 | 7 |